Consolidated Balance Sheets - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Current assets
Cash and cash equivalents	$ 84,978	$ 62,381
Property, plant and improvements
Property and equipment, net	14,576	16,343
Improvements in process	1,430,839	1,270,115
Other assets
Other receivables	222,562
Note receivable - related party	44,859
Deferred lease expense	217,210
Advances to CEN Biotech Ukraine LLC - related party	775,328	425,328
Intangible assets, net	6,230,583	6,655,396
Total assets	9,020,935	8,429,563
Current liabilities
Accounts payable	92,842	157,055
Accounts payable – related parties	11,986	62,994
Loans payable	9,981,883	9,962,287
Loans payable – related parties	838,923	846,448
Convertible notes payable	1,461,979
Convertible notes payable- related parties	2,210,313
Accrued interest	4,540,692	2,567,856
Accrued interest – related parties	592,901	256,762
Accrued expenses	295,874	840,582
Total current liabilities	20,027,393	14,693,984
Patent acquisition liability	5,000,000	5,000,000
Loans payable – related parties, less current portion	300,000
Convertible notes, less current portion	2,208,193	569,412
Convertible notes - related parties, less current portion	500,000	2,210,313
Total liabilities	28,035,586	22,473,709
Commitments and contingencies
Shareholders’ deficit
Special Voting Shares; unlimited authorized shares; No shares issued or outstanding at December 31, 2017, 100,000 issued and outstanding as of December 31, 2016, respectively.		10
Common stock; unlimited authorized shares; 21,169,343 and 6,851,843 issued and outstanding as of December 31, 2017 and 2016, respectively. No par value.
Additional paid-in capital	9,110,041	82
Accumulated deficit	(28,124,692)	(14,044,238)
Total shareholders’ deficit	(19,014,651)	(14,044,146)
Total liabilities and shareholders’ deficit	$ 9,020,935	$ 8,429,563